940958-93-0Relevant articles and documents
PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
-
Paragraph 1082-1084, (2020/01/04)
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
Substituted pyrazoles as novel sEH antagonist: Investigation of key binding interactions within the catalytic domain
Lo, Ho Yin,Man, Chuk C.,Fleck, Roman W.,Farrow, Neil A.,Ingraham, Richard H.,Kukulka, Alison,Proudfoot, John R.,Betageri, Raj,Kirrane, Tom,Patel, Usha,Sharma, Rajiv,Hoermann, Mary Ann,Kabcenell, Alisa,Lombaert, Stéphane De
scheme or table, p. 6379 - 6383 (2010/12/19)
A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent sEH inhibitors with favorable CYP3A4 inhibitory and microsomal stability profiles.
STEROIDAL [3, 2-C] PYRAZOLE COMPOUNDS, WITH GLUCOCORTICOID ACTIVITY
-
Page/Page column 80-81, (2009/05/29)
The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
